Pharma-Bio Serv, Inc. reported its financial results for the third quarter of fiscal year 2025, revealing a total revenue of $1.96 million for the three months ended July 31, 2025, a decrease of 18.9% compared to $2.42 million in the same period last year. For the nine-month period, revenues totaled $6.85 million, down from $7.18 million in the prior year. The company experienced a net loss of $204,250 for the quarter, an improvement from a loss of $309,194 in the same quarter of 2024. The nine-month net loss also decreased to $100,361 from $793,730 year-over-year.
The decline in revenue was attributed to reduced project activity in the Puerto Rico, United States, and Brazil consulting markets, which collectively saw a revenue drop of approximately $1.3 million. However, the European market showed resilience, with a revenue increase of about $1 million, contributing positively to the overall gross profit margin, which improved to 31.5% for the nine-month period, up from 24.9% in the previous year. This increase in gross profit percentage was primarily driven by enhanced margins in the Puerto Rico and United States consulting markets, alongside a high-margin project in Europe.
Operationally, Pharma-Bio Serv's total current assets decreased to $13.16 million as of July 31, 2025, down from $15.70 million at the end of the previous fiscal year. The company reported a significant reduction in cash and cash equivalents, which fell to $3.96 million from $6.77 million. The total liabilities also decreased to $1.66 million from $2.58 million, reflecting a strategic focus on managing expenses and liabilities. The company’s employee headcount remained stable, with no significant changes reported.
In terms of strategic developments, Pharma-Bio Serv continues to pursue geographic expansion and strengthen its business development infrastructure. The company is actively involved in marketing its services through industry trade shows and professional conventions, aiming to enhance its presence in the pharmaceutical, chemical, and biotechnology sectors. The management is also focused on renegotiating a tax grant with the Puerto Rico Industrial Development Company, which expired in October 2024, to secure continued tax relief for its operations.
Looking ahead, Pharma-Bio Serv's management expressed cautious optimism regarding future performance, emphasizing the importance of adapting to market conditions and potential regulatory changes. The company remains committed to leveraging its expertise in compliance consulting to navigate challenges posed by economic fluctuations and industry consolidations. The management believes that the current level of working capital and operational cash flows will be sufficient to meet anticipated expenses and contractual commitments in the coming year.
About Pharma-Bio Serv, Inc.
Pharma-Bio Serv provides compliance consulting services to the pharmaceutical, biotech, medical device, cosmetic, and food industries. Its core offerings include regulatory compliance, validation, technology transfer, and engineering services across Puerto Rico, the U.S., Europe, and Brazil. The company leverages experienced professionals to serve major clients, focusing on quality, regulatory adherence, and market expansion within a fragmented, competitive industry.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.